Did baricitinib work well for juvenile idiopathic arthritis eye inflammation?
Baricitinib is a type of medication called a targeted synthetic DMARD used to treat juvenile idiopathic arthritis (JIA). While newer drugs like this are approved for JIA, specific research on its ability to treat eye inflammation has produced mixed results. A major study found that it did not meet its primary goal of helping enough patients reduce eye inflammation at the 24-week mark.
What the research says
Other treatments for JIA, such as tumor necrosis factor (TNF) inhibitors, are well-established options for reducing joint symptoms and preventing damage 15. However, baricitinib belongs to a newer class of drugs called targeted synthetic DMARDs, which are distinct from TNF inhibitors 5. The current data indicates that for patients with JIA eye inflammation who have not responded to methotrexate or biologics, baricitinib may not be the most effective next step 4.
What to ask your doctor
- Is baricitinib an appropriate option for my child's specific type of eye inflammation?
- What are the success rates of baricitinib for reducing inflammation in the eyes compared to other medications?
- Are there other treatments that might work better for JIA-associated uveitis in patients who have not responded to methotrexate or biologics?
- What are the potential side effects of baricitinib for a child with JIA?
This question is drawn from common patient questions about Ophthalmology and answered using cited medical research. We do not provide individualized advice.